Analysis for IQV

📈 Growth & Financial Trajectory

Over the 7 quarters from 2024 Q4 to 2026 Q2, IQVIA's revenues rose from about $3.90B to $4.37B, a roughly 12% increase. However, net income declined from about $437M to $258M, a drop near 41%, signaling margin compression even as top-line growth persisted. The trend shows improving cash generation but weakening net profitability in later periods, with revenue gains insufficient to offset higher costs.

💰 Margins & Cash Flow

Gross margins are in the low-to-mid 20s, while operating margins have trended from the 16% range in 2024 to around 12% in 2025–2026, indicating some operating leverage pressure. Operating cash flow remained positive across periods, with notable quarterly cash from operations near $0.44B–$0.91B. Investing cash flow was negative in several periods, reflecting capex and investments. Overall, cash flow from operations supports liquidity but cash usage in investing and financing is nontrivial.

🛡️ Balance Sheet & Liquidity

Total assets around $29–$30B and liabilities around $23–$24B with equity near $6–$6.3B. The debt-to-equity ratio is elevated (roughly 3.7x), and current ratio historically under 1x in several periods, signaling liquidity constraints. Nonetheless, operating cash flow remains positive, lending resilience.

⚠️ Key Drivers & Risks

• Drivers: AI/Data analytics demand in life sciences and large-scale healthcare data processing.
• Risks: Leverage and liquidity risk; revenue growth sensitivity to client renewals and regulatory changes.